Arava and Ibandronate sodium drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Arava (leflunomide) and Ibandronate sodium (ibandronate sodium). Common drug interactions include atypical femur fracture among females and osteonecrosis among males.

The phase IV clinical study analyzes what interactions people have when they take Arava and Ibandronate sodium. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Arava?

Arava has active ingredients of leflunomide. It is often used in rheumatoid arthritis. eHealthMe is studying from 76,040 Arava users. Check the latest studies of Arava.

What is Ibandronate sodium?

Ibandronate sodium has active ingredients of ibandronate sodium. It is often used in osteoporosis post-menopausal. eHealthMe is studying from 3,549 Ibandronate sodium users. Check the latest studies of Ibandronate sodium.

On Jul, 17, 2026

11 people who take Arava and Ibandronate sodium together, and have interactions are studied.

Arava and Ibandronate sodium drug interactions.

What are the common drug interactions of Arava and Ibandronate Sodium, by gender? *:

female:

Atypical femur fracture
Dyspepsia (indigestion)
Femur fracture
Fracture displacement
Fracture nonunion (permanent failure of healing following a broken bone)
Increased tendency to bruise (increased tendency to injure the underlying soft tissue or bone)
Low turnover osteopathy (slow removal of old bone and its replacement by new bone)
Pain
Pain in extremity
Pathological fracture (broken bone caused by disease)

male:

Osteonecrosis (death of bone)
Acne conglobata (unpleasant form of nodulocystic acne-skin disease)
Pyrexia (fever)
Renal failure (kidney dysfunction)
Respiratory distress (difficulty in breathing)
Skin lesion
Device dislocation
Disease progression
Drug abuse
Ejection fraction decreased (systolic heart failure)

What are the common drug interactions of Arava and Ibandronate Sodium, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

Osteonecrosis (death of bone)
Acne conglobata (unpleasant form of nodulocystic acne-skin disease)
Device dislocation
Disease progression
Drug abuse
Ejection fraction decreased (systolic heart failure)
Eosinophilia (eosinophil count in the peripheral blood exceeds)
Face oedema (swelling of face)
Lipase increased
Pruritus (severe itching of the skin)

30-39:

n/a

40-49:

n/a

50-59:

Abdominal discomfort
Atypical femur fracture
Pain
Pain in extremity
Pathological fracture (broken bone caused by disease)
Skeletal injury (bone and supporting muscle injury)
Stress fracture (fracture of a bone caused by repeated (rather than sudden) mechanical stress)
Thyroiditis (inflammation of thyroid gland)
Vitamin d decreased
Bursitis (inflammation of a bursa, typically one in the knee, elbow, or shoulder)

60+:

n/a

What are the existing conditions these people have? *

Osteoporosis (bones weak and more likely to break): 4 people, 36.36%
Myocardial Ischaemia (the blood flow through one or more of the blood vessels that lead to heart (coronary arteries) is decreased): 1 person, 9.09%
Lymph Node Tuberculosis: 1 person, 9.09%
Juvenile Arthritis (arthritis-related condition that develops in children or teenagers): 1 person, 9.09%
Gout (uric acid crystals building up in the body): 1 person, 9.09%
Cardiac Failure Congestive: 1 person, 9.09%
Cardiac Failure: 1 person, 9.09%
Breast Cancer: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Arava and Ibandronate sodium?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously